China's innovative drugs are accelerating their overseas expansion and have entered an era of scale development worth billions of US dollars. According to relevant data statistics, the total amount of product authorization for overseas expansion has approached 140 billion US dollars since 2026, and it is expected to exceed 2025 for the whole year of this year. Entering November, the trend of domestic innovative drugs going global continues.
On November 5th, Haichuang Pharmaceutical announced that it has reached an exclusive licensing agreement with Evommune, a biopharmaceutical company focused on developing innovative therapies for chronic inflammatory diseases, for the highly efficient and selective oral VAV1 molecular gel degradation agent HP570 independently developed by Haichuang Pharmaceutical using a targeted protein degradation technology platform.
VAV1 is an important signaling protein involved in T cell and B cell activation, mainly expressed in immune cells. HP570 induces the degradation of VAV1 protein through molecular gel, regulating abnormal immune activity associated with autoimmune diseases. Compared to the JAK family proteins widely expressed in various tissues, the expression distribution of VAV1 provides a mechanistic basis for its potential safety and tolerability differences, and the related clinical benefits need to be validated through trials.
Evommune will make a down payment of a total of 30 million US dollars to Haichuang Pharmaceutical; Haichuang Pharmaceutical also has the right to receive up to approximately 1.07 billion US dollars in potential development, regulatory registration, and commercialization milestone payments, as well as tiered royalty fees based on net sales in the licensed area. In addition, under the agreement, Haichuang Pharmaceutical will have the right to obtain additional sub license shares.
On November 4th, Boehringer Ingelheim and China Biopharmaceutical Co., Ltd. announced a strategic multi project option and licensing agreement to advance potential next-generation cancer treatment options based on antibody coupled drug (ADC) and T cell adaptor (TcE) technologies. This collaboration covers six preclinical projects for biopharmaceuticals. Five of the projects are from Lixin Pharmaceutical, a wholly-owned subsidiary of China Biopharmaceutical Group, and the other project is from Beijing Taide Pharmaceutical, a subsidiary of the group.
As a further deepening of the existing cooperation in the field of oncology between the two parties, this new collaboration will combine the innovative technology platform and early research and development capabilities of China Biopharmaceutical Group, as well as Boehringer Ingelheim's professional advantages in global oncology research and development, to promote new treatment methods for patients worldwide.
According to the terms of the agreement, China Biopharmaceutical Group will receive a down payment of $358 million and recent payments, and is eligible for potential milestone payments for option exercise, development, regulation, and commercialization, totaling $7 billion. In addition, for products that will be successfully launched in the future, China Biopharmaceutical Group will also receive tiered royalties based on sales revenue.
On November 2nd, Xiyuan Anjian announced the latest developments in its exclusive licensing agreement with AbbVie. Both parties signed the agreement in 2024. According to the cooperation agreement, Xiyuan Anjian is responsible for drug discovery work, and AbbVie leads the global development and commercialization of two preclinical migraine projects for Xiyuan Anjian. According to the terms of the agreement, the potential total transaction value (including development, commercialization, regulatory, and sales milestone payments) can reach up to $757 million, plus future product sales revenue sharing.
Behind the continuous landing of transactions is the transformation of the underlying logic of China's innovative pharmaceutical industry. In the early years, domestic innovative drugs mainly relied on product introduction when going global. Nowadays, they have shifted to independent research and development assets for external authorization, and their target layout closely follows the forefront of the field. For local pharmaceutical companies, license out can not only quickly recoup funds, feed back subsequent R&D investment, reduce the financial pressure of long-term clinical development, but also leverage the mature global clinical, registration, and commercialization network of multinational pharmaceutical companies to enable Chinese source innovation to benefit global patients more quickly. For multinational pharmaceutical companies, collaborating with domestic innovation teams is an important path to low-cost supplementation of early pipelines and filling in the gaps of cutting-edge technology. The two-way demand has contributed to the sustained popularity of the BD market.